Skip to main content

Agios Pharmaceuticals, Inc.

AGIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001439222

In the last 90 days, Agios Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 238 institutions reported holding it in 13F filings for Q2 2026, worth $2.45B in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Agios Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of AGIO: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders1463170+27
Shares59.0M45.8K59.9M+975.7K (+1.7%)
Value$1.46B$1.13M$1.33B−$128.2M (−8.8%)

3 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (35)

Institutions that held Agios Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to AGIO in Q4 2023
InstitutionSharesValue% of portfolio
Walleye Capital LLC336,462$7.49M0.11%
Boothbay Fund Management, LLC286,445$6.38M0.24%
Qube Research & Technologies Ltd117,512$2.62M0.01%
Gsa Capital Partners LLP104,115$2.32M0.19%
ExodusPoint Capital Management, LP101,114$2.25M0.03%
Trexquant Investment LP54,541$1.21M0.03%
Two Sigma Investments, LP45,923$1.02M0.00%
OrbiMed Advisors LLC45,000$1.00M0.02%
Renaissance Technologies LLC42,714$951.0K0.00%
Campbell & CO Investment Adviser LLC42,686$950.6K0.09%
Allen Investment Management LLC36,166$805.4K0.01%
Tudor Investment Corp Et Al27,898$621.3K0.01%
Point72 Middle East FZE27,754$618.1K0.04%
Engineers Gate Manager LP24,586$547.5K0.02%
Schroder Investment Management Group24,000$534.5K0.00%
Nebula Research & Development LLC23,338$519.7K0.16%
Walleye Trading LLC20,321$452.5K0.01%
Brevan Howard Capital Management LP18,544$413.0K0.04%
Jump Financial, LLC16,240$361.7K0.01%
Pennant Investors, LP15,100$336.3K0.10%
Bayesian Capital Management, LP10,800$240.5K0.03%
Connor, Clark & Lunn Investment Management Ltd.10,131$225.6K0.00%
NEOS Investment Management LLC9,438$210.2K0.02%
Propel Bio Management, LLC5,792$129.0K0.11%
Cubist Systematic Strategies, LLC4,067$90.6K0.00%
EntryPoint Capital, LLC3,461$77.1K0.07%
Quest Partners LLC1,863$41.5K0.01%
Aspect Partners, LLC361$8.04K0.01%
Advisory Services Network, LLC350$7.79K0.00%
Private Wealth Management Group, LLC84$1.87K0.00%
EverSource Wealth Advisors, LLC59$1.31K0.00%
Farther Finance Advisors, LLC47$1.05K0.00%
GAMMA Investing LLC11$2490.00%
Principal Securities, Inc.10$2230.00%
DiNuzzo Private Wealth, Inc.1$230.00%

Sold out (8)

Institutions that held Agios Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of AGIO in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Marshall Wace, LLP58,040$1.44M
Simplex Trading, LLC21,006$519.0K
Northcape Wealth Management, LLC10,010$247.7K
SEI Investments Co9,752$241.4K
C M Bidwell & Associates Ltd85$2.10K
Parallel Advisors, LLC23$569
Earnest Partners LLC8$198
Allworth Financial LP5$124

Not filed for Q4 2023 yet (3)

Institutions that held Agios Pharmaceuticals, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AGIO in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
International Biotechnology Trust PLC24,000$593.5K
Virginia Retirement Systems Et Al21,800$539.5K
Steward Financial Group LLC9$0